CAPR

Company Overview — What Does CAPRICOR THERAPEUTICS, INC. Do?

Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives. Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases. Our lead product, deramiocel (also referred to as CAP-1002) is a cell therapy designed to treat Duchenne muscular dystrophy (DMD), the most severe form of muscular dystrophy, which results in muscle degeneration and premature death. Capricor’s innovative exosome technology is focusing on engineering exosomes to treat or prevent diseases with high unmet medical needs. Our translational approach to product development is based on the strong research foundation provided by our academic partnerships with leading scientists at top-tier research institutions. CAPRICOR THERAPEUTICS, INC. (CAPR) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Linda Marbán and employs approximately 101 people, headquartered in Beverly Hills, California. With a market capitalization of $1.7B, CAPR is one of the notable companies in the Healthcare sector.

CAPRICOR THERAPEUTICS, INC. (CAPR) Stock Rating — Hold (April 2026)

As of April 2026, CAPRICOR THERAPEUTICS, INC. receives a Hold rating with a composite score of 34.3/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.CAPR ranks #1,460 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CAPRICOR THERAPEUTICS, INC. ranks #123 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CAPR Stock Price and 52-Week Range

CAPRICOR THERAPEUTICS, INC. (CAPR) currently trades at $31.20. The stock lost $0.41 (1.3%) in the most recent trading session. The 52-week high for CAPR is $40.37, which means the stock is currently trading -22.7% from its annual peak. The 52-week low is $4.30, putting the stock 625.6% above its annual trough. Recent trading volume was 744K shares, suggesting relatively thin trading activity.

Is CAPR Overvalued or Undervalued? — Valuation Analysis

CAPRICOR THERAPEUTICS, INC. (CAPR) carries a value factor score of 33/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 21.92x, versus the sector average of 2.75x. The price-to-sales ratio is 812.96x, compared to 1.66x for the average Healthcare stock.

At current multiples, CAPRICOR THERAPEUTICS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CAPRICOR THERAPEUTICS, INC. Profitability — ROE, Margins, and Quality Score

CAPRICOR THERAPEUTICS, INC. (CAPR) earns a quality factor score of 17/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -104.3%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -69.2% versus the sector average of -33.1%.

The operating margin is -575.2% (sector: -66.1%). Net profit margin stands at -555.2%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CAPR Debt, Balance Sheet, and Financial Health

CAPRICOR THERAPEUTICS, INC. has a debt-to-equity ratio of 51.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 3.59x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $20M.

CAPR has a beta of 1.62, meaning it is more volatile than the broader market — a $10,000 investment in CAPR would be expected to move 61.9% more than the S&P 500 on any given day. The stability factor score for CAPRICOR THERAPEUTICS, INC. is 12/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

CAPRICOR THERAPEUTICS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, CAPRICOR THERAPEUTICS, INC. reported revenue of $2M and earnings per share (EPS) of $-0.54. Net income for the quarter was $-87M. Operating income came in at $-92M.

In Q3 2025, CAPRICOR THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.54. Net income for the quarter was $-25M. Operating income came in at $-26M.

In Q2 2025, CAPRICOR THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.57. Net income for the quarter was $-26M. Operating income came in at $-28M.

In Q1 2025, CAPRICOR THERAPEUTICS, INC. reported revenue of $0 and earnings per share (EPS) of $-0.53. Net income for the quarter was $-24M. Operating income came in at $-25M.

Over the past 8 quarters, CAPRICOR THERAPEUTICS, INC. has experienced revenue contraction from $5M to $2M. Investors analyzing CAPR stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CAPR Dividend Yield and Income Analysis

CAPRICOR THERAPEUTICS, INC. (CAPR) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CAPR Momentum and Technical Analysis Profile

CAPRICOR THERAPEUTICS, INC. (CAPR) has a momentum factor score of 71/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 15/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

CAPR vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CAPRICOR THERAPEUTICS, INC. (CAPR) ranks #123 out of 838 stocks based on the Blank Capital composite score. This places CAPR in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CAPR against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CAPR vs S&P 500 (SPY) comparison to assess how CAPRICOR THERAPEUTICS, INC. stacks up against the broader market across all factor dimensions.

CAPR Next Earnings Date

No upcoming earnings date has been announced for CAPRICOR THERAPEUTICS, INC. (CAPR) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CAPR? — Investment Thesis Summary

CAPRICOR THERAPEUTICS, INC. presents a balanced picture with arguments on both sides. The quality score of 17/100 flags below-average profitability. The value score of 33/100 indicates premium valuation. Price momentum is positive at 71/100, suggesting the trend favors buyers. High volatility (stability score 12/100) increases portfolio risk.

In summary, CAPRICOR THERAPEUTICS, INC. (CAPR) earns a Hold rating with a composite score of 34.3/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CAPR stock.

Related Resources for CAPR Investors

Explore more research and tools: CAPR vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CAPR head-to-head with peers: CAPR vs AZN, CAPR vs SLGL, CAPR vs VMD.